-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Theragnostics announced that it has signed an intellectual property licensing agreement with AstraZeneta that will enable the company to operate globally in selected radionuclide-labeled PARPi diagnostics.
The agreement strengthens Theragnostics' intellectual property posture and enables the company to accelerate the development of its rPARPi treatment and diagnostic portfolio.
The company is developing molecular radiotherapy for imaging and treating a variety of cancers, and the platform is able to develop PARPi-based molecular radiotherapy for imaging and treating cancer.
It uses radioatomic modification of PARPi drug molecules to produce radionuclide PARPi (rPARPi), which can be used for diagnostic use of PARP imaging in cancer patients, or radioisotopes can be used to deliver therapeutic doses of radioisotope cells to tumors, providing the potential for molecular targeted radiation to hit and kill tumor cells while avoiding damage to healthy cells and associated side effects.
Currently, at least four approved traditional drugs, PARPi, have been approved in several markets in recent months for new and expanded allergies.
Gareth Smith, chief operating officer of Theragnostics, said, "The company believes that radionuclide PARPi therapy will play a role independently of mutations in DNA (such as BRCA1/BRCA2) associated with PARPi activity enhancement and will avoid the development of therapeutic resistance." As a result, the number of patients benefiting from PARPi treatment may be significantly expanded.PARP inhibitors are a new class of tumor drugs that block an enzyme (poly (ADP-UC) polymerase, the response of cancer cells to DNA damage, caused by endogenous and chemotherapy treatments. (cyy123.com)